News for DRI Healthcare Trust (DHT-U.TO)

Capital Deployment: $457 million in committed capital, with $290 million as upfront investment.Credit Facilities: Expanded from $500 million to $632 million.Ca

Editas Medicine stock hits 52-week low at $2.7 amid market challenges

Total Cash Receipts: $38.9 million, a 54% increase over the same quarter in 2023.Total Income: $41.6 million, a 22% increase over the same quarter in 2023.Adju

Nov 07, 2024 / 01:00PM GMTOperator (technical difficulty) Responses to questions may contain forward-looking statements within the meaning of the safe harbour p

Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Editas Medicine, Inc.

**media[443277]**

Editas advances gene editing treatment for blood disorders

Read about Editas Medicine selling future license fees to DRI Healthcare Trust for $57 million, bringing in non-dilutive capital for pipeline development.

Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities...